177 related articles for article (PubMed ID: 28662296)
1. Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability.
Berry JD; Paganoni S; Atassi N; Macklin EA; Goyal N; Rivner M; Simpson E; Appel S; Grasso DL; Mejia NI; Mateen F; Gill A; Vieira F; Tassinari V; Perrin S
Muscle Nerve; 2017 Dec; 56(6):1077-1084. PubMed ID: 28662296
[TBL] [Abstract][Full Text] [Related]
2. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.
Laroni A; Brogi D; Brescia Morra V; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL
Neurol Sci; 2017 Jan; 38(1):53-59. PubMed ID: 27757552
[TBL] [Abstract][Full Text] [Related]
5. Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment.
Bianco A; Patanella AK; Nociti V; De Fino C; Lucchini M; Savio FL; Rossini PM; Mirabella M
Mult Scler Relat Disord; 2016 Sep; 9():11-3. PubMed ID: 27645336
[TBL] [Abstract][Full Text] [Related]
6. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
[TBL] [Abstract][Full Text] [Related]
7. Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study.
Paolicelli D; Manni A; Direnzo V; D'Onghia M; Tortorella C; Zoccolella S; Trojano M
J Clin Pharmacol; 2015 Oct; 55(10):1131-6. PubMed ID: 25903516
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.
Weiss MD; Macklin EA; Simmons Z; Knox AS; Greenblatt DJ; Atassi N; Graves M; Parziale N; Salameh JS; Quinn C; Brown RH; Distad JB; Trivedi J; Shefner JM; Barohn RJ; Pestronk A; Swenson A; Cudkowicz ME;
Neurology; 2016 Apr; 86(16):1474-81. PubMed ID: 26911633
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial).
Mandrioli J; D'Amico R; Zucchi E; Gessani A; Fini N; Fasano A; Caponnetto C; Chiò A; Dalla Bella E; Lunetta C; Mazzini L; Marinou K; Sorarù G; de Biasi S; Lo Tartaro D; Pinti M; Cossarizza A;
Medicine (Baltimore); 2018 Jun; 97(24):e11119. PubMed ID: 29901635
[TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.
Fragoso YD
Acta Neurol Belg; 2017 Dec; 117(4):821-827. PubMed ID: 28528469
[TBL] [Abstract][Full Text] [Related]
11. Oral fingolimod (FTY720) for relapsing multiple sclerosis.
Kappos L; Antel J; Comi G; Montalban X; O'Connor P; Polman CH; Haas T; Korn AA; Karlsson G; Radue EW;
N Engl J Med; 2006 Sep; 355(11):1124-40. PubMed ID: 16971719
[TBL] [Abstract][Full Text] [Related]
12. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
Ward MD; Jones DE; Goldman MD
Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
[TBL] [Abstract][Full Text] [Related]
13. Central Autonomic Dysfunction Delays Recovery of Fingolimod Induced Heart Rate Slowing.
Hilz MJ; Intravooth T; Moeller S; Wang R; Lee DH; Koehn J; Linker RA
PLoS One; 2015; 10(7):e0132139. PubMed ID: 26147106
[TBL] [Abstract][Full Text] [Related]
14. Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis.
Montalban X; Comi G; Antel J; O'Connor P; de Vera A; Cremer M; Sfikas N; von Rosenstiel P; Kappos L
J Neurol; 2015 Dec; 262(12):2627-34. PubMed ID: 26338810
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
Fox E; Edwards K; Burch G; Wynn DR; LaGanke C; Crayton H; Hunter SF; Huffman C; Kim E; Pestreich L; McCague K; Barbato L;
Mult Scler Relat Disord; 2014 Sep; 3(5):607-19. PubMed ID: 26265273
[TBL] [Abstract][Full Text] [Related]
16. First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
Hughes B; Cascione M; Freedman MS; Agius M; Kantor D; Gudesblatt M; Goldstick LP; Agashivala N; Schofield L; McCague K; Hashmonay R; Barbato L;
Mult Scler Relat Disord; 2014 Sep; 3(5):620-8. PubMed ID: 26265274
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Fingolimod in an Unselected Patient Population.
Rasenack M; Rychen J; Andelova M; Naegelin Y; Stippich C; Kappos L; Lindberg RL; Sprenger T; Derfuss T
PLoS One; 2016; 11(1):e0146190. PubMed ID: 26734938
[TBL] [Abstract][Full Text] [Related]
18. Impact of an immune modulator fingolimod on acute ischemic stroke.
Fu Y; Zhang N; Ren L; Yan Y; Sun N; Li YJ; Han W; Xue R; Liu Q; Hao J; Yu C; Shi FD
Proc Natl Acad Sci U S A; 2014 Dec; 111(51):18315-20. PubMed ID: 25489101
[TBL] [Abstract][Full Text] [Related]
19. Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis.
Gündüz T; Kürtüncü M; Eraksoy M
Mult Scler Relat Disord; 2017 Jan; 11():1-3. PubMed ID: 28104247
[No Abstract] [Full Text] [Related]
20. Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS.
Fox EJ; Lublin FD; Wolinsky JS; Cohen JA; Williams IM; Meng X; Ziehn M; Kolodny S; Cree BAC
Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31511330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
